Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Author:
Funder
Janssen Research and Development
Janssen Pharmaceuticals
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Link
https://link.springer.com/content/pdf/10.1007/s40264-023-01361-w.pdf
Reference84 articles.
1. Armstrong A, Bohannan B, Mburu S, Alarcon I, Kasparek T, Toumi J, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12:1055–64. https://doi.org/10.1007/s13555-022-00695-0.
2. Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, et al. New frontiers in psoriatic disease research, part II: comorbidities and targeted therapies. J Invest Dermatol. 2021;141:2328–37. https://doi.org/10.1016/j.jid.2021.02.743.
3. Novelli L, Lubrano E, Venerito V, Perrotta FM, Marando F, Curradi G, et al. Extra-articular manifestations and comorbidities in psoriatic disease: a journey into the immunologic crosstalk. Front Med. 2021;8: 737079. https://doi.org/10.3389/fmed.2021.737079.
4. Lebwohl M, Langley RG, Paul C, Puíg L, Reich K, van de Kerkhof P, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12:61–78. https://doi.org/10.1007/s13555-021-00635-4.
5. Samartín-Ucha M, Pego-Reigosa JM, Álvarez-Payero M, Martin-Vila A, Pineiro-Corrales G, Rodriguez-Rodriguez M, et al. Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study. Eur J Hosp Pharm. 2021;28(Suppl 2):e47-50. https://doi.org/10.1136/ejhpharm-2019-002133.
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16
2. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16
3. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study;Clinical Rheumatology;2024-06-07
4. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study;BMC Rheumatology;2024-05-21
5. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3